Takeda Pharmaceutical has agreed to acquire Envoy Therapeutics for a total consideration of up to US$140 M, including upfront and preclinical milestone payments. With the acquisition, Takeda will gain access to Envoy’s bacTRAP® technology for the identification of novel targets expressed in disease-relevant cell populations and its preclinical CNS assets, which include programmes for Parkinson’s disease and cognitive impairment associated with schizophrenia. Takeda Ventures has held a 12.5% stake in Envoy since 2009.